GlassScriptPhysician profile
Matthew Stroud
NPI 1164917910
$1,396.75
in general payments reported to CMS, 2019-2025
13 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $465 · 2024: $533 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $184.47 | 2023 | |
| Amgen INC. | $156.84 | 2025 | Evenity |
| Cochlear Americas | $148.78 | 2024 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha, Osia Osi300 Implant |
| Madrigal Pharmaceuticals | $129.92 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.97 | 2024 | Xifaxan |
| Neurelis, INC. | $112.66 | 2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $100.62 | 2023 | Austedo Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $99.99 | 2024 | |
| Alexion Pharmaceuticals, INC. | $99.52 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $93.07 | 2023-2024 | Dupixent |
| Silk Road Medical, INC. | $65.37 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Abbvie INC. | $60.42 | 2023 | |
| Phathom Pharmaceuticals, INC. | $22.12 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Stroud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.